RU2007109518A - Противомикробные пептиды, содержащие аргинин-и лизин-содержащий мотив - Google Patents
Противомикробные пептиды, содержащие аргинин-и лизин-содержащий мотив Download PDFInfo
- Publication number
- RU2007109518A RU2007109518A RU2007109518/04A RU2007109518A RU2007109518A RU 2007109518 A RU2007109518 A RU 2007109518A RU 2007109518/04 A RU2007109518/04 A RU 2007109518/04A RU 2007109518 A RU2007109518 A RU 2007109518A RU 2007109518 A RU2007109518 A RU 2007109518A
- Authority
- RU
- Russia
- Prior art keywords
- spp
- peptide
- amino acids
- pathogen
- peptide according
- Prior art date
Links
- 102000044503 Antimicrobial Peptides Human genes 0.000 title 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 18
- 150000001413 amino acids Chemical class 0.000 claims abstract 11
- 239000003814 drug Substances 0.000 claims abstract 4
- -1 cationic amino acids Chemical class 0.000 claims abstract 3
- 230000002209 hydrophobic effect Effects 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000004475 Arginine Substances 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 244000053095 fungal pathogen Species 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 244000052769 pathogen Species 0.000 claims 3
- 230000001717 pathogenic effect Effects 0.000 claims 3
- 239000000758 substrate Substances 0.000 claims 3
- 241000223682 Exophiala Species 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 241000194017 Streptococcus Species 0.000 claims 2
- 241000223238 Trichophyton Species 0.000 claims 2
- 241001459572 Trichophyton interdigitale Species 0.000 claims 2
- 241000223229 Trichophyton rubrum Species 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 230000000813 microbial effect Effects 0.000 claims 2
- 241000235389 Absidia Species 0.000 claims 1
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 claims 1
- 241000187362 Actinomadura Species 0.000 claims 1
- 241000293035 Apophysomyces Species 0.000 claims 1
- 241000985243 Arthrographis Species 0.000 claims 1
- 241000228212 Aspergillus Species 0.000 claims 1
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- 241000193738 Bacillus anthracis Species 0.000 claims 1
- 241000235579 Basidiobolus Species 0.000 claims 1
- 241000223679 Beauveria Species 0.000 claims 1
- 241000335423 Blastomyces Species 0.000 claims 1
- 241000589968 Borrelia Species 0.000 claims 1
- 241001453380 Burkholderia Species 0.000 claims 1
- 241000589876 Campylobacter Species 0.000 claims 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 1
- 241000222122 Candida albicans Species 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- 241001647372 Chlamydia pneumoniae Species 0.000 claims 1
- 241001647378 Chlamydia psittaci Species 0.000 claims 1
- 241000606153 Chlamydia trachomatis Species 0.000 claims 1
- 241000123346 Chrysosporium Species 0.000 claims 1
- 241001112696 Clostridia Species 0.000 claims 1
- 241000193155 Clostridium botulinum Species 0.000 claims 1
- 241000223203 Coccidioides Species 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 241001480517 Conidiobolus Species 0.000 claims 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 241001123635 Dipodascus Species 0.000 claims 1
- 241001262659 Emmonsia Species 0.000 claims 1
- 241000588914 Enterobacter Species 0.000 claims 1
- 241000194033 Enterococcus Species 0.000 claims 1
- 241000194032 Enterococcus faecalis Species 0.000 claims 1
- 241001480035 Epidermophyton Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000589602 Francisella tularensis Species 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 241000159512 Geotrichum Species 0.000 claims 1
- 241000190550 Graphium <Microascales incertae sedis> Species 0.000 claims 1
- 241000606790 Haemophilus Species 0.000 claims 1
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- 241000589989 Helicobacter Species 0.000 claims 1
- 241000590002 Helicobacter pylori Species 0.000 claims 1
- 241000228402 Histoplasma Species 0.000 claims 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 241000526728 Lacazia Species 0.000 claims 1
- 241000228456 Leptosphaeria Species 0.000 claims 1
- 241000186781 Listeria Species 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 241000555676 Malassezia Species 0.000 claims 1
- 241001480037 Microsporum Species 0.000 claims 1
- 241000235395 Mucor Species 0.000 claims 1
- 206010065764 Mucosal infection Diseases 0.000 claims 1
- 241000186359 Mycobacterium Species 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 241000588653 Neisseria Species 0.000 claims 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims 1
- 241000588650 Neisseria meningitidis Species 0.000 claims 1
- 241000322230 Neotestudina Species 0.000 claims 1
- 241000187654 Nocardia Species 0.000 claims 1
- 241000203622 Nocardiopsis Species 0.000 claims 1
- 208000010195 Onychomycosis Diseases 0.000 claims 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 1
- 241001236817 Paecilomyces <Clavicipitaceae> Species 0.000 claims 1
- 241000222831 Phialophora <Chaetothyriales> Species 0.000 claims 1
- 241001503951 Phoma Species 0.000 claims 1
- 241001326501 Piedraia Species 0.000 claims 1
- 241000223596 Pseudallescheria Species 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 241000812330 Pyrenochaeta Species 0.000 claims 1
- 241000235402 Rhizomucor Species 0.000 claims 1
- 241000235527 Rhizopus Species 0.000 claims 1
- 241000223252 Rhodotorula Species 0.000 claims 1
- 241000235070 Saccharomyces Species 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 241000132889 Scedosporium Species 0.000 claims 1
- 241000122799 Scopulariopsis Species 0.000 claims 1
- 241000607768 Shigella Species 0.000 claims 1
- 241000607762 Shigella flexneri Species 0.000 claims 1
- 241000222068 Sporobolomyces <Sporidiobolaceae> Species 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- 241000193996 Streptococcus pyogenes Species 0.000 claims 1
- 241000736854 Syncephalastrum Species 0.000 claims 1
- 208000002474 Tinea Diseases 0.000 claims 1
- 241000130764 Tinea Species 0.000 claims 1
- 241000589886 Treponema Species 0.000 claims 1
- 241000223259 Trichoderma Species 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 241000082085 Verticillium <Phyllachorales> Species 0.000 claims 1
- 241000607734 Yersinia <bacteria> Species 0.000 claims 1
- 241000607479 Yersinia pestis Species 0.000 claims 1
- 229940065181 bacillus anthracis Drugs 0.000 claims 1
- 244000052616 bacterial pathogen Species 0.000 claims 1
- 229940038705 chlamydia trachomatis Drugs 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940032049 enterococcus faecalis Drugs 0.000 claims 1
- 229940118764 francisella tularensis Drugs 0.000 claims 1
- 229940047650 haemophilus influenzae Drugs 0.000 claims 1
- 229940037467 helicobacter pylori Drugs 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 229960003104 ornithine Drugs 0.000 claims 1
- 230000003071 parasitic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 1
- 239000004753 textile Substances 0.000 claims 1
- 201000005882 tinea unguium Diseases 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 244000052613 viral pathogen Species 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
- C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Claims (26)
1. Пептид, его вариант или его фармацевтически приемлемая соль, содержащие аминокислоты формулы I:
где I и m представляют собой целые числа от 0 до 10; n представляет собой целое число от 1 до 10; Х и Y, которые могут быть одинаковыми или разными, представляют собой аминокислоты, выбранные из группы, состоящей из гидрофобных аминокислот и/или катионных аминокислот, для применения в качестве фармацевтического средства.
2. Пептид по п.1, где Х и Y выбраны из группы катионных аминокислот, состоящей из орнитина, гистидина, аргинина и лизина.
3. Пептид по п.2, где Х и Y выбраны из аргинина и лизина.
4. Пептид по п.1, где Х и Y являются одинаковыми.
5. Пептид по п.4, где Х и Y представляют собой аргинин.
6. Пептид по любому из пп.1-5, содержащий от 3 до примерно 200 аминокислот.
7. Пептид по п.6, содержащий от 3 до 100 аминокислот.
8. Пептид по п.7, содержащий от 3 до 50 аминокислот.
9. Пептид по п.8, содержащий от 3 до 15 аминокислот.
10. Пептид по п.9, содержащий от 3 до 7 аминокислот.
11. Композиция, содержащая фармацевтически эффективное количество по меньшей мере одного пептида по любому из пп.1-10 и фармацевтически приемлемый носитель, эксципиент или разбавитель.
12. Применение пептида или его варианта по любому из пп.1-10 в изготовлении лекарственного средства для лечения микробной инфекции.
13. Применение по п.12, где микробная инфекция вызвана бактериальным, паразитическим, протозойным, вирусным или грибковым патогеном.
14. Применение по п.13, где бактериальный патоген принадлежит к виду бактерий, выбранному из группы, состоящей из: Staphylococcus spp., например Staphylococcus aureus, Staphylococcus epidermidis; Enterococcus spp., например Enterococcus faecalis; Streptococcus pyogenes; Listeria spp.; Pseudomonas spp.; Mycobacterium spp., например Mycobacterium tuberculosis; Enterobacter spp.; Campylobacter spp.; Salmonella spp.; Streptococcus spp., например Streptococcus группы А или В, Streptococcus pneumoniae; Helicobacter spp., например Helicobacter pylori; Neisseria spp., например Neisseria gonorrhea, Neisseria meningitidis; Borrelia burgdorfen; Shigella spp., например Shigella flexneri; Escherichia coli; Haemophilus spp., например Haemophilus influenzae; Chlamydia spp., например Chlamydia trachomatis, Chlamydia pneumoniae, Chlamydia psittaci; Francisella tularensis; Bacillus spp., например Bacillus anthracis; Clostridia spp., например Clostridium botulinum; Yersinia spp., например Yersinia pestis; Treponema spp.; Burkholderia spp.; например Burkholdena mallei и S pseudomallei.
15. Применение по п.13, где грибковый патоген происходит от грибкового патогена из рода Candida spp.(например C.albicans), Epidermophyton spp., Exophiala spp., Microsporum spp., Trichophyton spp.(например T.rubrum и T.interdigitale), Tinea spp., Aspergillus spp., Blastomyces spp., Blastoschizomyces spp., Coccidioides spp., Cryptococcus spp., Histoplasma spp., Paracoccidiomyces spp., Sporotrix spp., Absidia spp., Cladophialophora spp., Fonsecaea spp., Phialophora spp., Lacazia spp., Arthrographis spp., Acremonium spp., Actinomadura spp., Apophysomyces spp., Emmonsia spp., Basidiobolus spp., Beauveria spp., Chrysosporium spp., Conidiobolus spp., Cunninghamella spp., Fusarium spp., Geotrichum spp., Graphium spp., Leptosphaeria spp., Malassezia spp., Mucor spp., Neotestudina spp., Nocardia spp., Nocardiopsis spp., Paecilomyces spp., Phoma spp., Piedraia spp., Pneumocystis spp., Pseudallescheria spp., Pyrenochaeta spp., Rhizomucor spp., Rhizopus spp., Rhodotorula spp., Saccharomyces spp., Scedosporium spp., Scopulariopsis spp., Sporobolomyces spp., Syncephalastrum spp., Trichoderma spp., Trichosporon spp., Ulocladium spp., Ustilago spp., Verticillium spp., Wangiella spp.
16. Применение по п.15, где патоген принадлежит к роду Trichophyton spp.
17. Применение по п.16, где патоген представляет собой Trichophyton interdigitale.
18. Применение по п.16, где патоген представляет собой Trichophyton rubrum.
19. Применение по п.12, где грибковая инфекция представляет собой онихомикоз.
20. Применение пептида или его варианта по любому из пп.1-10 в изготовлении лекарственного средства для лечения инфекции слизистой оболочки.
21. Применение по п.20, где инфекция представляет собой муковисцидоз.
22. Субстрат, к которому прикреплен или на который нанесен пептид или пептидный вариант по любому из пп.1-10.
23. Субстрат по п.22, где этот субстрат содержит текстильный или коллагеновый материал.
24. Применение пептида или его варианта по любому из пп.1-10 в изготовлении лекарственного средства для лечения раны.
25. Применение по п.24, где рана представляет собой порез или ожог.
26. Применение пептида или его варианта по любому из пп.1-10 в изготовлении лекарственного средства для лечения язвы.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0418414.9 | 2004-08-18 | ||
| GBGB0418414.9A GB0418414D0 (en) | 2004-08-18 | 2004-08-18 | Peptide |
| US7979505A | 2005-03-14 | 2005-03-14 | |
| US11/079,795 | 2005-03-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007109518A true RU2007109518A (ru) | 2008-09-27 |
| RU2396273C2 RU2396273C2 (ru) | 2010-08-10 |
Family
ID=35907779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007109518/04A RU2396273C2 (ru) | 2004-08-18 | 2005-08-18 | Противомикробные пептиды, содержащие аргинин- и лизинсодержащий мотив |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US7847059B2 (ru) |
| EP (5) | EP3141559A1 (ru) |
| JP (1) | JP5020078B2 (ru) |
| KR (1) | KR101234780B1 (ru) |
| CN (3) | CN103360485A (ru) |
| AT (1) | ATE479704T1 (ru) |
| AU (1) | AU2005273638B2 (ru) |
| BR (1) | BRPI0514420B1 (ru) |
| CA (2) | CA2974538A1 (ru) |
| CY (1) | CY1113684T1 (ru) |
| DE (1) | DE602005023315D1 (ru) |
| DK (2) | DK1927597T3 (ru) |
| ES (1) | ES2613027T3 (ru) |
| GB (1) | GB2431404A (ru) |
| IL (2) | IL180727A (ru) |
| MX (1) | MX2007002057A (ru) |
| NO (1) | NO342832B1 (ru) |
| NZ (2) | NZ584340A (ru) |
| PL (1) | PL1778720T3 (ru) |
| PT (2) | PT1778720E (ru) |
| RU (1) | RU2396273C2 (ru) |
| SG (3) | SG155211A1 (ru) |
| SI (1) | SI1778720T1 (ru) |
| WO (1) | WO2006018652A2 (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2478396C2 (ru) * | 2008-11-05 | 2013-04-10 | ВАЙЕТ ЭлЭлСи | МНОГОКОМПОНЕНТНАЯ ИММУНОГЕННАЯ КОМПОЗИЦИЯ ДЛЯ ПРЕДУПРЕЖДЕНИЯ ЗАБОЛЕВАНИЯ, ВЫЗВАННОГО β-ГЕМОЛИТИЧЕСКИМИ СТРЕПТОКОККАМИ (БГС) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8252737B2 (en) | 2004-12-15 | 2012-08-28 | The Regents Of The University Of Colorado | Antimicrobial peptides and methods of use |
| US9181303B2 (en) | 2005-12-22 | 2015-11-10 | Novabiotics Limited | Treatment of bacterial infections with cyclic antimicrobial peptides |
| AU2012203804B2 (en) * | 2005-12-22 | 2014-10-16 | Novabiotics Limited | Cyclic antimicrobial peptides |
| EP2357190A3 (en) * | 2005-12-22 | 2011-08-24 | Novabiotics Limited | Cyclic antimicrobial peptides |
| GB0702020D0 (en) | 2007-02-02 | 2007-03-14 | Novabiotics Ltd | Peptides and their use |
| GB0702022D0 (en) * | 2007-02-02 | 2007-03-14 | Novabiotics Ltd | Peptides and their use |
| GB0702021D0 (en) * | 2007-02-02 | 2007-03-14 | Novabiotics Ltd | Peptides and their use |
| KR101717275B1 (ko) * | 2007-07-26 | 2017-03-16 | 레반스 테라퓨틱스, 아이엔씨. | 항미생물 펩티드, 조성물, 및 이용 방법 |
| US20100150985A1 (en) * | 2008-04-24 | 2010-06-17 | George Just | Dental Implant, Endodontic Instrument, and Dental Filling Material Coated with a Peptide-Based Antimicrobial and Methods of Using and Making the Same |
| GB0817121D0 (en) * | 2008-09-18 | 2008-10-29 | Univ St Andrews | Anti-fungal therapy |
| CA2739842A1 (en) * | 2008-10-06 | 2010-04-15 | The Regents Of The University Of Colorado, A Body Corporate | Antimicrobial peptides and methods of use |
| US20100184683A1 (en) | 2009-01-06 | 2010-07-22 | C3 Jian, Inc. | Antibacterial and antifungal peptides |
| FR2941231B1 (fr) * | 2009-01-16 | 2016-04-01 | Sederma Sa | Nouveaux peptides, compositions les comprenant et utilisations cosmetiques et dermo-pharmaceutiques. |
| GB0905451D0 (en) * | 2009-03-31 | 2009-05-13 | Novabiotics Ltd | Biofilms |
| EP2437770A4 (en) * | 2009-06-05 | 2013-11-06 | Univ Colorado Regents | ANTIMICROBIAL PEPTIDES |
| JP5664992B2 (ja) * | 2009-08-26 | 2015-02-04 | 国立大学法人名古屋大学 | 細胞特異的ペプチド及びその用途 |
| EP2547700A1 (en) * | 2010-03-17 | 2013-01-23 | Universität Regensburg | Peptides or antibodies which bind to melanoma inhibitory activity (mia) protein |
| CN102206250B (zh) | 2010-03-29 | 2017-03-15 | 翔升科技股份有限公司 | 低血球溶解性的抗微生物肽、药物组合物及其用途 |
| GB201016733D0 (en) | 2010-10-05 | 2010-11-17 | Novabiotics Ltd | Compounds and their use |
| GB201021186D0 (en) | 2010-12-14 | 2011-01-26 | Novabiotics Ltd | Composition |
| RU2449805C1 (ru) | 2011-01-27 | 2012-05-10 | Общество С Ограниченной Ответственностью "Гармония" | Пептидная фармацевтическая композиция, средство на ее основе для лечения гастродуоденальных заболеваний, вызываемых helicobacter pylori, и способ его использования |
| CA2829516C (en) | 2011-03-11 | 2020-08-18 | Vib Vzw | Molecules and methods for inhibition and detection of proteins |
| DE102011077071A1 (de) * | 2011-06-07 | 2012-12-13 | Beiersdorf Ag | Wirkstoffkombinationen aus Epsilon-Polylysin und Climbazol |
| KR101345333B1 (ko) * | 2011-12-30 | 2013-12-30 | 조선대학교산학협력단 | 라이신 및 트립토판 잔기가 ４번 반복된 신규한 항균 및 항진균 펩타이드 및 이의 용도 |
| GB201204457D0 (en) * | 2012-03-14 | 2012-04-25 | Novabiotics Ltd | Polypeptides and their use |
| US9744191B2 (en) | 2012-03-19 | 2017-08-29 | Yale University | Antimicrobial compositions and methods |
| RU2680959C2 (ru) | 2012-03-23 | 2019-03-01 | Амикроб, Инк. | Композиции и применение противомикробных материалов со свойствами биологической совместимости |
| US20140120077A1 (en) | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and Methods for Safe Treatment of Rhinitis |
| EP2958429A4 (en) * | 2013-02-20 | 2016-10-05 | Biolog Inc | COMPOSITIONS AND METHODS FOR INACTIVATION AND / OR REDUCTION OF MICROBIAL TOXIN PRODUCTION |
| RU2683651C2 (ru) * | 2013-06-18 | 2019-04-01 | Иван Дмитриевич Захаров | Лекарственное средство для лечения кератоконуса и других дегенеративных заболеваний роговицы и фармацевтические препараты на его основе |
| GB201409451D0 (en) | 2014-05-28 | 2014-07-09 | Ipabc Ltd | Antimicrobial preparations, methods for preparing the same and uses thereof to combat microorganisms |
| WO2015195458A1 (en) * | 2014-06-17 | 2015-12-23 | Albert Einstein College Of Medicine, Inc. | Therapeutic nanoparticles and methods thereof |
| US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| GB201416727D0 (en) * | 2014-09-22 | 2014-11-05 | Novabiotics Ltd | Use |
| CN104311627B (zh) * | 2014-10-29 | 2018-04-10 | 中山大学 | 一种抗菌肽的合成方法和应用 |
| EP3106172B1 (de) * | 2015-06-15 | 2020-08-05 | B. Braun Melsungen AG | Antimikrobiell aktive mittel und deren verwendung |
| JP2019510076A (ja) * | 2016-02-19 | 2019-04-11 | フォルシュングスツェントルム ボルシュテル ライプニッツツェントルム フュール メディツィン ウント ビオヴィッセンシャフテン | 細菌感染症を治療するための手段と方法 |
| WO2018144545A1 (en) | 2017-01-31 | 2018-08-09 | Stc.Unm | Arginine-rich polypeptide compositions and methods of using same |
| US11285189B2 (en) | 2017-04-06 | 2022-03-29 | Amicrobe, Inc. | Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety |
| US11931333B1 (en) * | 2019-05-28 | 2024-03-19 | Peter Van Horn | Topical treatment of herpes infections |
| CN112457375B (zh) * | 2019-09-06 | 2022-12-02 | 韩苏 | 多肽化合物及其制备方法与应用 |
| CN113307848B (zh) * | 2021-05-31 | 2023-11-17 | 安徽农业大学 | 具有抗真菌和清除自由基活性的环色-丝-缬-异亮-亮肽及制备方法 |
| CN113264987B (zh) * | 2021-05-31 | 2023-11-17 | 安徽农业大学 | 具有抗真菌和清除自由基活性的环色-苏-缬-异亮-亮肽及制备方法 |
| CN115669843A (zh) * | 2022-10-26 | 2023-02-03 | 中国农业大学 | 一种采用高压微射流结合混合肽有效杀灭芽孢的方法 |
| CN116332777A (zh) * | 2023-02-20 | 2023-06-27 | 华中科技大学 | 二芳基苯甲胺类化合物、制备及作为载体合成多肽的应用 |
| GB202311426D0 (en) * | 2023-07-25 | 2023-09-06 | Novabiotics Ltd | Cosmetic nail formulations |
| GB202400182D0 (en) * | 2024-01-05 | 2024-02-21 | Novabiotics Ltd | Improved compositions to improve the appearance and/or condition of skin, scalp, nail and/or hair |
| CN119235837B (zh) * | 2024-12-02 | 2025-03-25 | 温州医科大学附属第一医院 | 一种专用于抗浅部真菌细菌感染的组合物及其制备方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3561444A (en) | 1968-05-22 | 1971-02-09 | Bio Logics Inc | Ultrasonic drug nebulizer |
| US3703173A (en) | 1970-12-31 | 1972-11-21 | Ted A Dixon | Nebulizer and tent assembly |
| US4051842A (en) | 1975-09-15 | 1977-10-04 | International Medical Corporation | Electrode and interfacing pad for electrical physiological systems |
| DE2626348C3 (de) | 1976-06-11 | 1980-01-31 | Siemens Ag, 1000 Berlin Und 8000 Muenchen | Implantierbare Dosiereinrichtung |
| WO1982001385A1 (en) | 1980-10-14 | 1982-04-29 | Zingel Heinz | Spinning frame,particularly ring spinning frame |
| US4383529A (en) | 1980-11-03 | 1983-05-17 | Wescor, Inc. | Iontophoretic electrode device, method and gel insert |
| US4635627A (en) | 1984-09-13 | 1987-01-13 | Riker Laboratories, Inc. | Apparatus and method |
| US4624251A (en) | 1984-09-13 | 1986-11-25 | Riker Laboratories, Inc. | Apparatus for administering a nebulized substance |
| US4962091A (en) | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
| DE59009460D1 (de) * | 1989-05-30 | 1995-09-07 | Siemens Ag | CMOS-ECL-Wandler. |
| CA2061862A1 (en) * | 1991-03-04 | 1992-09-05 | Jonathan Duvick | Natural and synthetic proteins with inhibitory activity towards pathogenic microorganisms |
| JP3022615B2 (ja) * | 1991-03-13 | 2000-03-21 | 日清製粉株式会社 | ε−ポリリジンの製造方法 |
| JP3000490B2 (ja) * | 1991-04-08 | 2000-01-17 | チッソ株式会社 | 抗白癬菌剤 |
| US5486503A (en) * | 1991-11-01 | 1996-01-23 | The Trustees Of Boston University | Anti-fungal histatin-based peptides |
| CA2145093C (en) | 1992-09-25 | 2007-04-10 | Lawrence Leroy Kunz | Therapeutic inhibitor of vascular smooth muscle cells |
| JP3655359B2 (ja) * | 1995-06-29 | 2005-06-02 | 株式会社サンコンタクトレンズ | 含水性ソフトコンタクトレンズの洗浄および消毒用組成物 |
| US5714577A (en) * | 1996-01-26 | 1998-02-03 | University Of Pittsburgh | Antimicrobial peptides |
| US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
| JPH11113779A (ja) * | 1997-10-14 | 1999-04-27 | Asahi Chem Ind Co Ltd | 除菌ウェットティッシュ |
| CN1347421A (zh) * | 1999-04-15 | 2002-05-01 | 伊莱利利公司 | 分离自丁香假单胞菌的抗真菌剂 |
| US20020001582A1 (en) * | 1999-04-21 | 2002-01-03 | Charter Edward A. | Methods and compositions for inhibiting microbial growth |
| JP2001264707A (ja) * | 2000-03-22 | 2001-09-26 | Chisso Corp | コンタクトレンズ用消毒保存用溶液 |
| JP2002020320A (ja) * | 2000-06-30 | 2002-01-23 | Santen Pharmaceut Co Ltd | 点眼液用防腐剤 |
| FR2811666B1 (fr) * | 2000-07-13 | 2005-04-01 | Entomed S A | Peptides antifongiques et/ou antibacteriens, leurs preparations et les compositions les contenant |
| CN1336383A (zh) * | 2000-07-29 | 2002-02-20 | 中国科学院昆明动物研究所 | 大蹼铃蟾抗菌肽及其制备方法和在制药中的应用 |
| RU2183643C1 (ru) * | 2000-12-18 | 2002-06-20 | Государственный научно-исследовательский институт особо чистых биопрепаратов | Пептид, обладающий биоцидной активностью |
| US7033991B2 (en) | 2001-07-16 | 2006-04-25 | Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College | Inhibiting furin with polybasic peptides |
| WO2003091429A1 (fr) * | 2002-04-25 | 2003-11-06 | Toagosei Co.,Ltd. | Polypeptide microbicide et ses utilisations |
| JP4461727B2 (ja) * | 2003-07-18 | 2010-05-12 | チッソ株式会社 | 外用剤組成物 |
| US20080193616A1 (en) * | 2007-02-13 | 2008-08-14 | The Coca-Cola Company | Beverage compositions comprising polylysine and at least one weak acid |
-
2005
- 2005-08-18 ES ES08001112.5T patent/ES2613027T3/es active Active
- 2005-08-18 CN CN2013101617432A patent/CN103360485A/zh active Pending
- 2005-08-18 PT PT05778505T patent/PT1778720E/pt unknown
- 2005-08-18 DK DK08001112.5T patent/DK1927597T3/en active
- 2005-08-18 PT PT80011125T patent/PT1927597T/pt unknown
- 2005-08-18 CA CA2974538A patent/CA2974538A1/en not_active Abandoned
- 2005-08-18 CN CN2005800281216A patent/CN101031583B/zh not_active Expired - Fee Related
- 2005-08-18 CN CN2013101618914A patent/CN103360486A/zh active Pending
- 2005-08-18 PL PL05778505T patent/PL1778720T3/pl unknown
- 2005-08-18 EP EP16176481.6A patent/EP3141559A1/en not_active Withdrawn
- 2005-08-18 NZ NZ584340A patent/NZ584340A/en not_active IP Right Cessation
- 2005-08-18 EP EP16179810.3A patent/EP3147293B1/en active Active
- 2005-08-18 JP JP2007526571A patent/JP5020078B2/ja active Active
- 2005-08-18 EP EP08001112.5A patent/EP1927597B1/en not_active Not-in-force
- 2005-08-18 NZ NZ553494A patent/NZ553494A/en not_active IP Right Cessation
- 2005-08-18 DK DK05778505.7T patent/DK1778720T3/da active
- 2005-08-18 US US11/573,770 patent/US7847059B2/en active Active
- 2005-08-18 BR BRPI0514420-5A patent/BRPI0514420B1/pt not_active IP Right Cessation
- 2005-08-18 EP EP09005438A patent/EP2096118A1/en not_active Withdrawn
- 2005-08-18 KR KR1020077003571A patent/KR101234780B1/ko active Active
- 2005-08-18 AU AU2005273638A patent/AU2005273638B2/en not_active Ceased
- 2005-08-18 SG SG200905379-4A patent/SG155211A1/en unknown
- 2005-08-18 RU RU2007109518/04A patent/RU2396273C2/ru active
- 2005-08-18 MX MX2007002057A patent/MX2007002057A/es active IP Right Grant
- 2005-08-18 CA CA2575058A patent/CA2575058C/en active Active
- 2005-08-18 AT AT05778505T patent/ATE479704T1/de active
- 2005-08-18 SG SG2013007356A patent/SG188092A1/en unknown
- 2005-08-18 DE DE602005023315T patent/DE602005023315D1/de active Active
- 2005-08-18 SI SI200531161T patent/SI1778720T1/sl unknown
- 2005-08-18 SG SG10201606278UA patent/SG10201606278UA/en unknown
- 2005-08-18 WO PCT/GB2005/003245 patent/WO2006018652A2/en not_active Application Discontinuation
- 2005-08-18 EP EP05778505A patent/EP1778720B1/en not_active Not-in-force
-
2007
- 2007-01-16 IL IL180727A patent/IL180727A/en active IP Right Grant
- 2007-02-19 GB GB0703060A patent/GB2431404A/en not_active Withdrawn
- 2007-03-14 NO NO20071369A patent/NO342832B1/no unknown
-
2010
- 2010-09-29 US US12/893,663 patent/US8088888B2/en active Active
- 2010-11-30 CY CY20101101093T patent/CY1113684T1/el unknown
-
2011
- 2011-06-02 IL IL213319A patent/IL213319A/en not_active IP Right Cessation
- 2011-06-28 US US13/170,975 patent/US8350003B2/en not_active Expired - Fee Related
- 2011-11-30 US US13/308,479 patent/US8470769B2/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2478396C2 (ru) * | 2008-11-05 | 2013-04-10 | ВАЙЕТ ЭлЭлСи | МНОГОКОМПОНЕНТНАЯ ИММУНОГЕННАЯ КОМПОЗИЦИЯ ДЛЯ ПРЕДУПРЕЖДЕНИЯ ЗАБОЛЕВАНИЯ, ВЫЗВАННОГО β-ГЕМОЛИТИЧЕСКИМИ СТРЕПТОКОККАМИ (БГС) |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007109518A (ru) | Противомикробные пептиды, содержащие аргинин-и лизин-содержащий мотив | |
| RU2008129866A (ru) | Циклические противомикробные пептиды | |
| Bessalle et al. | All-D-magainin: chirality, antimicrobial activity and proteolytic resistance | |
| AU2016210742B2 (en) | Inhibition of biofilm organisms | |
| Lee et al. | Fungicidal mechanisms of the antimicrobial peptide Bac8c | |
| Fanaei et al. | Microbial assisted (Bacillus mojavensis) production of bio-surfactant lipopeptide with potential pharmaceutical applications and its characterization by MALDI-TOF-MS analysis | |
| US12036267B2 (en) | Lactoferricin and lactoferrampin for treating infections | |
| Jung et al. | Effective antibacterial action of tat (47-58) by increased uptake into bacterial cells in the presence of trypsin | |
| WO2001012668A1 (en) | Cathelicidin-derived peptides with broad spectrum antimicrobial activity | |
| US7348402B2 (en) | Antimicrobial peptide, its analogs and antimicrobial composition comprising them | |
| EP0349451B1 (fr) | Molécules peptidiques à action sur les germes à Gram positif | |
| Bartie et al. | In vitro susceptibility of the Streptococcus milleri group to antimicrobial peptides | |
| CN109485701B (zh) | 抗菌肽、抗菌药物以及制备方法 | |
| CN118440967B (zh) | 一种具有抗菌活性的sprr2a原核表达系统及其构建方法和应用 | |
| Du et al. | Growth stimulation of bacterium Delftia by a peptide hydrogel | |
| JP5207286B2 (ja) | 抗微生物活性ペプチド | |
| Marcos et al. | Antimicrobial peptides | |
| Özbek et al. | Lysine-based non-cytotoxic ultrashort self-assembling peptides with antimicrobial activity | |
| FR2738841A1 (fr) | Procede de polymerisation de sequences d'acides nucleiques et ses applications | |
| JP5158538B2 (ja) | 抗微生物活性増強ペプチド及びそれを含む抗微生物剤 | |
| Krishnamoorthy et al. | Design and Synthesis of N-terminal segment Peptides: A New Innovative Finding for Antimicrobial Activity | |
| WO2014058985A1 (en) | High-throughput assays for enzyme inhibitors and peptide inhibitors against hiv-1 and methods for using them | |
| Zheng et al. | Metabolic labeling-mediated visualization, capture, and inactivation of Gram-positive bacteria via biotin–streptavidin interactions | |
| CN106995485A (zh) | 一种分离的内源性抗菌多肽及其应用 | |
| Shobana | Expression and production optimization of the cationic antimicrobial peptide-indolicidin by the recombinant E. coli C41 (DE3) clones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| QB4A | Licence on use of patent |
Free format text: LICENCE Effective date: 20150505 |
|
| QC41 | Official registration of the termination of the licence agreement or other agreements on the disposal of an exclusive right |
Free format text: LICENCE FORMERLY AGREED ON 20150505 Effective date: 20201002 |